Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Advanced Therapies 2021 | The benefits of umbilical cord-derived MSCs as a cell source

Mathias Svahn, PhD, MScEng, NextCell Pharma AB, Huddinge, Sweden, gives an overview of the use and benefits of umbilical cord (UC)-derived mesenchymal stem cell (MSC) as a cell source for cell-based therapeutics. Compared to bone marrow-derived MSCs, which have been under investigation in a range of autoimmune conditions and graft-versus-host disease for a number of years, UC-MSCs have more recently started being utilized and investigated. UC-MSCs constitute a young, potent and fast-growing source of cells that can be obtained from discarded tissue, thus reducing ethical implications. This interview took place at the Advanced Therapies Congress & Expo 2021.


Mathias Svahn is the founder, shareholder and CEO of NextCell Pharma AB.